E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Multiple sclerosis
|
Esclérosis múltiple |
|
E.1.1.1 | Medical condition in easily understood language |
Multiple sclerosis |
Esclérosis múltiple |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028245 |
E.1.2 | Term | Multiple sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10063400 |
E.1.2 | Term | Secondary progressive multiple sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10063399 |
E.1.2 | Term | Relapsing-remitting multiple sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10063401 |
E.1.2 | Term | Primary progressive multiple sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effectiveness of repeated TXB infiltrations on gait in patients with Multiple Sclerosis who presented limb spasticity less than 4 weeks after infiltration and its maintenance over time at 12 months, using objective results obtained by the clinician (6MWT ) and reported by the patient (MSWS-12). |
Evaluar la efectividad de infiltraciones repetidas de TXB en la marcha, en pacientes con Esclerosis Múltiple que presentan espasticidad de miembros inferiores a las 4 semanas de la infiltración y su mantenimiento en el tiempo a los 12 meses, mediante resultados objetivos obtenidos por el clínico (6MWT) y reportados por el paciente (MSWS-12) . |
|
E.2.2 | Secondary objectives of the trial |
- Evaluation of spasticity (Modified Ashworth Spasticity scale - MAS scale). - Evaluation of disability (EDSS scale). - Evaluation of the quality of life after the use of botulinum toxin type A (MSQoL-54). - Assessment of medium and long-term objectives (GAS scale). - Evaluation of tolerance and side effects. |
- Evaluación del grado de espasticidad mediante la escala de espasticidad de Ashworth modificada (escala MAS). - Evaluación de la discapacidad (escala EDSS ). - Evaluación la calidad de vida tras el uso de toxina botulínica tipo A (MSQoL-54). - Valoración de los objetivos a medio y largo plazo (escala GAS). - Evaluación de tolerancia y efectos secundarios. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Acceptance and signature of informed consent. - Age between 18 and 80 years old, both included. - Patients with relapsing remitting multiple sclerosis (RRMS), progressive secondary (SP) and primary progressive (PP), with spasticity resistant to usual treatment, either because of the severity of the spasticity or because of intolerance to side effects. - Outpatients with spastic paraparesis that causes gait deficiency. - Patients with an EDSS score between 2 and 6, both included. - Patients with segmental involvement in MAS >1 in two or more muscle groups in the lower extremities. - Absence of cognitive disability. Score less than 5 on the SPMSQ scale of Pfeiffer. - Possibility of carrying out the treatment (method of administration, scheduled visits) and scales correctly. - Women of childbearing potential should use an effective contraceptive method (hormonal contraceptives, intrauterine device, condom) or refrain from having sex in order not to get pregnant. A woman is considered to be fertile after menarche and to become postmenopausal, unless she has undergone a permanent sterilization procedure (hysterectomy, salpingectomy, bilateral oophorectomy). A postmenopausal state is defined as absence of menstruation for 12 months without an alternative medical cause. |
- Aceptación y firma del consentimiento informado. - Edad entre 18 y 80 años, ambos incluidos. - Pacientes con esclerosis múltiple remitente recurrente (EMRR), secundaria progresiva (SP) y primaria progresiva (PP), con espasticidad resistente a tratamiento habitual, ya sea por la severidad de la espasticidad o por la intolerancia a los efectos secundarios. - Pacientes ambulatorios con paraparesia espástica que causa deficiencia en la marcha. - Pacientes con una puntuación EDSS entre 2 y 6, ambos incluidos. - Pacientes con afectación segmental en MAS >1 en dos o más grupos musculares en extremidades inferiores. - Ausencia de discapacidad cognitiva. Puntación menor de 5 en la escala SPMSQ de Pfeiffer. - Posibilidad de realizar el tratamiento (forma de administración, visitas programadas) y las escalas correctamente. - Las mujeres en edad fértil deben utilizar un método anticonceptivo eficaz (anticonceptivos hormonales, dispositivo intrauterino, preservativo) o abstenerse de mantener relaciones sexuales con el fin de no quedarse embarazada. Se considera que una mujer es fértil después de la menarquia y hasta convertirse en posmenopáusica, a menos que se haya sometido a un procedimiento de esterilización permanente (histerectomía, salpingectomía, ooforectomía bilateral). Un estado posmenopáusico se define como ausencia de menstruación durante 12 meses sin una causa medica alternativa. |
|
E.4 | Principal exclusion criteria |
- Psychiatric illness that hinders participation in the trial. - Comorbidity that threatens the patient's life in the short term (severe liver disease, cardiovascular disease, etc.). - Osteoarticular disorder that prevents physical activity. - Pregnancy or lactation. - Lack of primary or secondary response to any type of TXB for the treatment of MS previously detected. - Sensitivity to TXB or to any excipient. - Any medical condition that, in the opinion of the investigator, may compromise compliance with the objectives and / or procedures of this protocol or preclude the administration of TXB. - Changes in the treatment regimen of any drug that directly or indirectly interferes with neuromuscular function within 4 weeks before the start of the study treatment. |
- Enfermedad psiquiátrica que dificulte la participación en el ensayo. - Comorbilidad que amenace la vida del paciente a corto plazo (enfermedad hepática severa, enfermedad cardiovascular, etc.). - Desorden osteoarticular que impida la actividad física. - Embarazo o lactancia. - Falta de respuesta primaria o secundaria a cualquier tipo de TXB para el tratamiento de EM detectada previamente. - Sensibilidad a TXB o a cualquier excipiente. - Cualquier condición médica que, en opinión del investigador, pueda comprometer el cumplimiento de los objetivos y/o procedimientos de este protocolo o imposibilitar la administración de TXB. - Modificaciones en la pauta de tratamiento de cualquier fármaco que interfiera directa o indirectamente con la función neuromuscular en las 4 semanas antes del inicio del estudio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Change from baseline observed in the maximum distance that a patient can walk in 6 minutes (6MWT) at 4 weeks after each infiltration. - Changes from baseline in the score obtained in the MSWS-12 scale, at 4 weeks after each infiltration. |
- Cambio observado en la distancia máxima que puede recorrer un paciente en 6 minutos (6MWT) a las 4 semanas tras cada infiltración en relación a la puntuación basal . - Cambios en la puntuación obtenida en la escala MSWS-12, a las 4 semanas tras cada infiltración en relación a la puntuación basal.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The values in these scales will be measured before the patient receives the treatment and 4 weeks after each injection. Each patient will undergo 3-4 treatment cycles of 12-16 weeks each. |
Los valores en dichas escalas serán medidos antes de que el paciente reciba el tratamiento y 4 semanas después de cada inyección. Cada paciente será sometido a 3-4 ciclos de tratamiento de duración de 12-16 semanas cada uno de ellos. |
|
E.5.2 | Secondary end point(s) |
- Change observed in the total score of the EDSS scale before and after the application of the treatment. - Observed change in the quality of life of patients before and after treatment, evaluated through the MSQoL-54 questionnaire. - Evaluation of the achievement of the treatment goal through the GAS scale. - Incidence of serious and not serious adverse reactions. - Incidence of serious and non-serious adverse events. - Tolerance to treatment. - Discontinuation due to adverse reactions. |
- Cambio observado en la puntuación total de la escala EDSS antes y después de la aplicación del tratamiento. - Cambio observado en la calidad de vida de los pacientes antes y después del tratamiento, evaluada a través del cuestionario MSQoL-54. - Evaluar si se ha alcanzado el objetivo del tratamiento a través de la escala GAS. - Incidencia de reacciones adversas graves y no graves. - Incidencia de acontecimientos adversos graves y no graves. - Tolerancia al tratamiento. - Discontinuación debido a reacciones adversas. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The values in these scales will be measured before the patient receives the treatment and 4 weeks after each injection. Each patient will undergo 3-4 treatment cycles of 12-16 weeks each. |
Los valores en dichas escalas serán medidos antes de que el paciente reciba el tratamiento y 4 semanas después de cada inyección. Cada paciente será sometido a 3-4 ciclos de tratamiento de duración de 12-16 semanas cada uno de ellos. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Ensayo clínico prospectivo de un solo brazo de bajo nivel de intervención. |
Prospective, single-arm, low-level intervention trial. |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
February 2021 |
Febrero 2021 |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 30 |
E.8.9.1 | In the Member State concerned days | |